These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
25. Enhancement of graft-versus-tumor activity and graft-versus-host disease by pretransplant immunization of allogeneic bone marrow donors with a recipient-derived tumor cell vaccine. Anderson LD; Petropoulos D; Everse LA; Mullen CA Cancer Res; 1999 Apr; 59(7):1525-30. PubMed ID: 10197624 [TBL] [Abstract][Full Text] [Related]
26. Delayed mortality in sublethally irradiated mice treated with allogeneic lymphoid and myeloid cells. Boranić M J Natl Cancer Inst; 1968 Aug; 41(2):439-50. PubMed ID: 4876446 [No Abstract] [Full Text] [Related]
28. [Quantitative aspects of modern radiation immunology and problem of the action of radiation on intercellular cooperative processes]. Petrov RV; Koval'chuk LV; Cheredeev AN Radiobiologiia; 1971; 11(4):483-94. PubMed ID: 4939572 [No Abstract] [Full Text] [Related]
29. Tissue culture studies of mouse mammary tumor cells and associated viruses. Owens RB; Hackett AJ J Natl Cancer Inst; 1972 Nov; 49(5):1321-32. PubMed ID: 4346536 [No Abstract] [Full Text] [Related]
30. Circulating immune complexes, antigens, and antibodies related to the murine mammary tumor virus in C3H mice. Dong ZW; Witkin SS; Fernandes G; Sarkar NH; Good RA; Day NK J Immunol; 1982 Aug; 129(2):872-6. PubMed ID: 6282972 [No Abstract] [Full Text] [Related]
31. Ubiquity of natural antibodies to the mammary tumour virus in mice. Bentvelzen P; Brinkhof J Arch Geschwulstforsch; 1980; 50(3):193-203. PubMed ID: 6254462 [TBL] [Abstract][Full Text] [Related]
32. Functional capacity of bone marrow modified by contact with antigenic substances. Uphoff DE; Draper LR J Natl Cancer Inst; 1971 Dec; 47(6):1233-40. PubMed ID: 5120409 [No Abstract] [Full Text] [Related]
33. [Effect of Ly49A transfected mouse spleen cells on graft versus host disease and graft versus leukemia after haploidentical allogeneic bone marrow transplantation in mice]. Li Y; Guo K; Chen Y; Song Z; Li J; Deng L Zhonghua Xue Ye Xue Za Zhi; 2002 Aug; 23(8):411-4. PubMed ID: 12411044 [TBL] [Abstract][Full Text] [Related]
34. In vitro modification of donor bone marrow used to produce enhanced graft survival in antilymphocyte serum (ALS)-treated mice. Gozzo JJ; Wood ML; Pompei R; Monaco AP Transplant Proc; 1973 Mar; 5(1):853-6. PubMed ID: 4572148 [No Abstract] [Full Text] [Related]
35. Mechanism of augmented graft survival in mice after ALS and bone marrow infusion. Wood ML; Heppner G; Gozzo JJ; Monaco AP Transplant Proc; 1973 Mar; 5(1):691-6. PubMed ID: 4572128 [No Abstract] [Full Text] [Related]
36. "Xenogeneic resistance" to rat bone marrow transplantation. II. Relationship of hemopoietic regeneration and survival. Rauchwerger JM; Gallagher MT; Trentin JJ Biomedicine; 1973 Mar; 18(2):109-11. PubMed ID: 4581501 [No Abstract] [Full Text] [Related]
37. Recovery from established graft-vs-host disease achieved by bone marrow transplantation from a third-party allogeneic donor. Taniguchi Y; Yoshihara S; Hoshida Y; Inoue T; Fujioka T; Ikegame K; Kawakami M; Masuda T; Aozasa K; Kawase I; Ogawa H Exp Hematol; 2008 Sep; 36(9):1216-25. PubMed ID: 18599183 [TBL] [Abstract][Full Text] [Related]
38. B and T cells are required for mouse mammary tumor virus spread within the mammary gland. Golovkina TV; Dudley JP; Ross SR J Immunol; 1998 Sep; 161(5):2375-82. PubMed ID: 9725233 [TBL] [Abstract][Full Text] [Related]